GNTA
Genenta Science S.p.A.
Healthcare — Biotechnology
Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Price History
Fundamentals
| Market Cap | $41.28M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.69 |
| EPS (TTM) | $-0.38 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -38.03% |
| Debt/Equity | 34.81 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 53.8 |
| Beta | 0.90 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $10.00 |
| 52-Week Low | $0.55 |
| 50-Day Avg | $1.19 |
| 200-Day Avg | $1.59 |
| Avg Volume | $1.50M |
| Volume | 57.7K |
Performance Analysis
NEUTRALGNTA presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:12 UTC
Back to Screener Export Report